

PAPER

# Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction

Qizhi Pei<sup>1,4</sup>, Lijun Wu<sup>2,\*</sup>, Jinhua Zhu<sup>3</sup>, Yingce Xia<sup>2</sup>, Shufang Xie<sup>1</sup>, Tao Qin<sup>2</sup>, Haiguang Liu<sup>2</sup>, Tie-Yan Liu<sup>2</sup> and Rui Yan<sup>1,5,\*</sup>

<sup>1</sup>Gaoling School of Artificial Intelligence, Renmin University of China, No.59, Zhong Guan Cun Avenue, Haidian District, 100872, Beijing, China, <sup>2</sup>Microsoft Research AI4Science, No.5, Dan Ling Street, Haidian District, 100080, Beijing, China, <sup>3</sup>CAS Key Laboratory of GIPAS, EEIS Department, University of Science and Technology of China, No.96, JinZhai Road, Baohe District, 230026, Hefei, Anhui Province, China, <sup>4</sup>Engineering Research Center of Next-Generation Intelligent Search and Recommendation, Ministry of Education and <sup>5</sup>Beijing Key Laboratory of Big Data Management and Analysis Methods

\*Corresponding authors: Lijun Wu, Microsoft Research AI4Science, Beijing, China, E-mail: lijunwu@microsoft.com; Rui Yan, Gaoling School of Artificial Intelligence, Renmin University of China, Beijing, China, E-mail: ruiyan@ruc.edu.cn

FOR PUBLISHER ONLY Received on Date Month Year; revised on Date Month Year; accepted on Date Month Year

## Abstract

Accurate prediction of Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery, facilitating the identification of drugs that can effectively interact with specific targets and regulate their activities. While wet experiments remain the most reliable method, they are time-consuming and resource-intensive, resulting in limited data availability that poses challenges for deep learning approaches. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. To overcome this challenge, we present the SSM-DTA framework, which incorporates three simple yet highly effective strategies: (1) A multi-task training approach that combines DTA prediction with masked language modeling (MLM) using paired drug-target data. (2) A semi-supervised training method that leverages large-scale unpaired molecules and proteins to enhance drug and target representations. This approach differs from previous methods that only employed molecules or proteins in pre-training. (3) The integration of a lightweight cross-attention module to improve the interaction between drugs and targets, further enhancing prediction accuracy. Through extensive experiments on benchmark datasets such as BindingDB, DAVIS, and KIBA, we demonstrate the superior performance of our framework. Additionally, we conduct case studies on specific drug-target binding activities, virtual screening experiments, drug feature visualizations, and real-world applications, all of which showcase the significant potential of our work. In conclusion, our proposed SSM-DTA framework addresses the data limitation challenge in DTA prediction and yields promising results, paving the way for more efficient and accurate drug discovery processes. Our code is available at <https://github.com/QizhiPei/SSM-DTA>.

**Key words:** Drug-Target Affinity Prediction, Data Scarcity, Multi-task Learning, Semi-supervised Learning, Masked Language Modeling

### Key Messages

- We propose a semi-supervised multi-task training framework with simple yet effective strategies for DTI prediction to alleviate the data limitation issue.
- We demonstrate the state-of-the-art performance of the SSM-DTA framework by conducting multiple experiments on DTI benchmark datasets.
- We provide extensive studies to show the potential of SSM-DTA, e.g., it can well capture the structural knowledge with accurate binding information between drugs and targets.

## Introduction

As healthcare management continues to advance, the research of drugs and their various applications, such as Drug-Drug Interactions (DDI), drug repurposing, drug synergy prediction,

and Drug-Target Interactions (DTI), has become increasingly important. Among these areas, the prediction of Drug-Target Affinity (DTA) is particularly crucial in drug research[1], as it involves accurately forecasting the binding effect of a drug to a protein target. While computational methods like molecular

docking [2] and molecular dynamics simulations [3] can be effective for predicting DTA, they can be costly due to their high computational demands.

Deep learning has been promising in recent years to predict drug-target affinity (DTA) due to its high accuracy and efficiency [4, 5, 6, 7]. However, the effectiveness of deep learning models relies heavily on the availability of large amounts of labeled training data. Unfortunately, there is a limited amount of labeled binding affinity data available for recognized drugs and targets, as collecting this data through experiments can be costly and time-consuming. For example, the commonly used BindingDB dataset contains approximately 2 million binding data points, but as noted in [5], the data is of low quality and the affinity labels for the same compound-protein pairs are often noisy due to various factors such as variations in experimental conditions and different data sources. After following the same data filtration protocols as [5], the remaining clean data only contains around 200k points, which is small compared to datasets in natural language processing and computer vision (which often contain millions to billions of data points) where deep learning has seen great success. This limited amount of labeled data poses a challenge for deep learning-based DTA prediction.

To address the issue of drug-target affinity (DTA) prediction, we present the Semi-Supervised Multi-task Training (SSM) framework. This framework includes three strategies to improve DTA prediction accuracy: (1) We conduct multi-task training on labeled drug-target pairs. Besides the DTA prediction task, we incorporate a masked language modeling (MLM) task [8] on both drugs and targets, which can effectively improve DTA prediction accuracy. (2) In addition, inspired by the success of self-supervised learning [9, 8], we leverage large-scale unlabeled molecule and protein data to help with drug and target representation learning. We find that common pre-training (on unlabeled data) and fine-tuning (on supervised data) paradigm can not work well in DTA prediction, since the separate pre-training on unlabeled molecule and protein ignores the importance of interaction between paired drug and target when fine-tuning. Therefore, we propose a different method to mix unlabeled data together with paired data and perform semi-supervised training for DTA prediction. (3) We introduce an efficient cross-attention module to explicitly capture interaction information between drugs and targets, further improving DTA prediction accuracy.

We evaluate SSM-DTA framework by conducting experiments on several benchmarks, including the BindingDB, DAVIS, and KIBA. The results showed that SSM-DTA significantly improved the accuracy of DTA prediction, for example, a large reduction in root-mean-square-error (RMSE) on the BindingDB IC<sub>50</sub> dataset, a 5% improvement over state-of-the-art methods. SSM-DTA also showed strong generalization ability on unknown drugs. In addition, case studies of drug-target binding activities showed that the model was able to accurately identify important atomic groups and amino acids within binding sites. The model’s ability to group drugs by their targets was also visualized, revealing good performance in this regard. Real-world applications of SSM-DTA framework to detect targets for drugs also demonstrated its strong generalization capabilities. Overall, these results highlight the potential of the SSM framework in DTA research. The main contributions are:

- We propose a semi-supervised multi-task training framework with simple yet effective strategies for DTI prediction to alleviate the data limitation issue.
- We demonstrate the state-of-the-art performance of the SSM-DTA framework by conducting multiple experiments on DTI benchmark datasets.
- We provide extensive studies to show the potential of SSM-DTA, e.g., it can well capture the structural knowledge with accurate binding information between drugs and targets.


## Related Work

### Drug-Target Interaction/Affinity Prediction

The DTI/DTA prediction methods can be classified into structure-based and structure-free approaches. For structure-based methods, molecular docking [10] and molecular dynamics (MD) simulations [3] are typical works, which require the 3D structure inputs of drug and protein and utilize predefined force fields to estimate the binding affinity at the atomic level. However, the strong dependency on high-quality 3D structures comes with a major limitation. Structure-free predictions are then developed. Similarity-based methods are popular, which calculate the similarity metrics as descriptors for drugs and targets to predict DTA [11], e.g., KronRLS [12] and SimBoost [13]. Recently, deep-learning-based methods are promising, such as DeepAffinity [5], MONN [14], GeneralizedDTA [15], FusionDTA [16], and others [4, 17, 18, 19], which usually adopt different networks (e.g., CNN, RNN, Transformers) on the labeled data for affinity prediction. DeepAffinity [5] employs unsupervised pre-training on a seq2seq RNN model using compound SMILES or protein SPS representations. GeneralizedDTA [15] is designed for unknown drug discovery, which combines self-supervised pre-training and multi-task learning with a dual adaptation mechanism to enhance protein and drug feature representation and improve generalization capability. FusionDTA [16] uses a multi-head linear attention mechanism for feature aggregation and knowledge distillation to reduce parameter redundancy, resulting in improved performance and efficiency in the DTA task. [19] uses transfer learning from chemical-chemical interaction (CCI) and protein-protein interaction (PPI) tasks to enhance drug-target interaction predictions.

### Molecule and Protein Pre-training

For molecule pre-training methods, there are two rough types based on molecule representations: the sequential model pre-train [20] based on the simplified molecular-input line-entry system (SMILES) [21] and the graph neural network (GNN) pre-train [22] based on the molecule graph structures. The SMILES-based pre-train typically takes the Transformer network, motivated by its excellent performances demonstrated on related fields, such as SMILES-BERT [23] and Chemberta [24]. Different GNN models are adopted for graph structure pre-train, and the pre-train tasks include masked training that are performed on different graph parts, such as N-gram [25], AttrMasking [22], ContextPredict [22], MotifPredict [26], and also the contrastive learning based methods [27]. Protein pre-train depends on the protein sequences, which are fed into Transformer encoder for pre-training [28]. Representative works include TAPE [29] and ESM [30]. The above works all take protein or molecule only for pre-train, without considering the relationship between them.



**Fig. 1.** The overall framework of our SSM-DTA. The two encoders are Transformers and take the drug/molecule and target/protein sequences as input respectively. The MLM (Masked Language Modeling) training is conducted on both unlabeled (unpaired) data and paired data. The cross-attention module is used between drug-target paired data, where Q is a query, K&V are key and value.

## Methods

**Preliminary** We first give the necessary notations and definitions of DTA prediction. Given a DTA dataset  $\mathcal{DT} = \{(D, T, y)_i\}_{i=1}^N$ , where  $(D, T, y)$  is the triplet of DTA data sample,  $N$  is the sample size,  $D$  is one drug from a drug dataset,  $T$  is one target from a target dataset, label  $y$  (a floating number) is the affinity for the  $(D, T)$  pair. DTA prediction is a regression task to predict the binding affinity score between the drug and target, learning a mapping function  $\mathcal{F} : D \times T \rightarrow y$ . The affinity score (label  $y$ ) is a quantitative measure of the strength of binding between a drug and target. We take the SMILES string as the representation of drugs, which is a sequence resulting from traversing the molecule graph using depth-first search and some specific rules, e.g.,  $D = \{d_i\}_{i=1}^{|D|}$ , where  $|D|$  is the length of SMILES and  $d_i$  is the token in the string. For a target  $T$ , we use the FASTA sequence of the protein, which consists of amino acid tokens, e.g.,  $T = \{t_i\}_{i=1}^{|T|}$ ,  $|T|$  is the length and  $t_i$  is the amino acid token. Similarly, the unlabeled molecule sequence is denoted as  $M = \{m_i\}_{i=1}^{|M|}$ , and the protein sequence is denoted as  $P = \{p_i\}_{i=1}^{|P|}$ .

The overall architecture of the SSM-DTA framework is illustrated in Figure 1. Our training data consists of three parts: paired drug-target data, unlabeled molecule data, and unlabeled protein sequences. The molecule and drug sequences are processed by a Transformer model [31]  $\mathcal{M}_D$ , and the protein and target sequences are processed by another Transformer model  $\mathcal{M}_T$ <sup>1</sup>. For the paired data  $(D, T)$ , the model performs

a regression task for DTA prediction and also undergoes MLM training. After encoding the drug and target sequences and obtaining the attended representations  $h_{D \rightarrow T}$  and  $h_{T \rightarrow D}$  through the cross-attention module, they are concatenated together for the final affinity prediction with an MLP prediction head. The unlabeled molecule and protein data are only used for MLM training.

Before feeding the paired drug and target sequences into  $\mathcal{M}_D$  and  $\mathcal{M}_T$ , we first add a special [cls] token at the beginning of the sequences. Specifically, the drug  $D$  and target  $T$  are formed as  $D = \{[cls]_D, \{d_i\}_{i=1}^{|D|}\}$  and  $T = \{[cls]_T, \{t_i\}_{i=1}^{|T|}\}$ . These sequences are then encoded by  $\mathcal{M}_D$  and  $\mathcal{M}_T$  to obtain hidden states  $H_D = \{h_{[cls]_D}, \{h_{d_i}\}_{i=1}^{|D|}\}$  and  $H_T = \{h_{[cls]_T}, \{h_{t_i}\}_{i=1}^{|T|}\}$ . The same operation is performed on unlabeled  $M$  and  $P$ .

**Interaction with Cross-attention Module** DTA prediction aims to predict the binding affinity resulting from the *interaction* between drug and target. Therefore it is important to model the interaction effectively. Recent [14, 5] have focused on the design of the interaction module and introduced the attention mechanism [32]. They use joint attention that operates on each token of drug and target sequences, resulting in a pairwise interaction attention matrix over all tokens, which requires high computational cost.

We introduce a lightweight cross-attention module, which is much simpler than the pairwise interaction mechanism. To calculate our cross-attention, we use the  $h_{[cls]_D}$  and  $h_{[cls]_T}$  elements of  $H_D$  and  $H_T$  to represent the drug  $D$  and target  $T$  respectively. Cross-attention is then performed between the [cls] tokens and the paired sequences, where the query is

<sup>1</sup> The detailed encoding process of Transformers  $\mathcal{M}_D$  and  $\mathcal{M}_T$  is introduced in the Appendix.

$h_{[cls]_D}$  or  $h_{[cls]_T}$ , and the key, value are  $H_T$  or  $H_D$ :

$$h_{D \rightarrow T} = \text{softmax}\left(\frac{(h_{[cls]_D} W_1)(H_T W_2)^T}{\sqrt{d}}\right)(H_T W_3),$$

$$h_{T \rightarrow D} = \text{softmax}\left(\frac{(h_{[cls]_T} W_4)(H_D W_5)^T}{\sqrt{d}}\right)(H_D W_6),$$

where  $d$  is the hidden dimension, and  $W$ s are parameter matrices. After the cross-attention, the attended representations are then concatenated and fed into an MLP head for DTA prediction.

$$y' = \text{MLP}(\llbracket h_{D \rightarrow T}, h_{T \rightarrow D} \rrbracket),$$

where MLP means multilayer perceptron,  $\llbracket \cdot \rrbracket$  means concatenation, and  $y'$  is the predicted binding affinity. The loss function for DTA task is the mean squared error (MSE):

$$\mathcal{L}_{mse} = (y - y')^2,$$

where  $y$  is the ground truth binding affinity.

### Multi-task Training with MLM

Since we are targeting alleviating the data limitation issue of DTA prediction, multi-task training [33, 34] is a preferred method that is widely adopted. In this work, inspired by the general self-supervised methods that take the masked language modeling (MLM) objective for pre-training [8, 9], we take the same spirit in our DTA prediction. Besides the DTA prediction, we introduce MLM to form a multi-task training. Note that both DTA prediction and MLM are conducted upon the original paired drug-target data.

For a drug  $D = \{d_i\}_{i=1}^{|D|}$  and target  $T = \{t_i\}_{i=1}^{|T|}$ , we follow [8] to randomly replace some of the tokens  $d_i, t_i$  in the sequence by a special [MASK] token with some mask ratios [8], and then try to recover the original sequence by the masked sequences  $D'$  and  $T'$ ,

$$\mathcal{L}_{mlm}^D = - \sum_{k=1}^{M_D} \log P(d_k \| D'), \mathcal{L}_{mlm}^T = - \sum_{k=1}^{M_T} \log P(t_k \| T'),$$

where  $d_k, t_k$  are the masked tokens,  $M_D, M_T$  are the masked token numbers in drug and target sequences,  $\log$  is log-likelihood, and  $P$  means the conditional probability. Both  $\mathcal{L}_{mlm}^D$  and  $\mathcal{L}_{mlm}^T$  are based on the negative log-likelihood of the masked tokens and the goal is to predict the original tokens from the masked sequences. During training, the MLM objectives are jointly optimized with DTA prediction to enhance drug and target representations. In this way, though we do not incorporate more labeled DTA data, we maximize the potential of the original DTA data.

### Semi-supervised Training with Large-scale Unlabeled Molecule and Protein Data

Pre-training on large amounts of unlabeled data in a self-supervised manner has shown promising results in natural language processing [8, 9], image processing [35], and video processing [36]. In the chemistry and biology domains, pre-trained models have also demonstrated success [22]. In this work, we also leverage large amounts of unlabeled molecules and proteins to enhance representation and address the issue of limited DTA data.

Unlike previous works [9] that adopted the widely used pre-training and fine-tuning strategy [8], we propose a semi-supervised learning approach that trains on both unlabeled and

supervised data. One major limitation of existing methods is that pre-training the molecules and proteins separately does not adequately capture the interaction between drugs and targets, which is critical for DTA prediction. This leads to poor performance when using the pre-training and fine-tuning method for DTA prediction (see Section 5.3). To address this issue, we propose a semi-supervised multi-task training method that combines regression training on labeled drug-target pairs with masked language modeling (MLM) on both labeled and unlabeled molecules and proteins. Similar to paired drug and target sequences, for an unlabeled molecule sequence  $M = \{m_i\}_{i=1}^{|M|}$  and protein sequence  $P = \{p_i\}_{i=1}^{|P|}$ , we also take MLM training,

$$\mathcal{L}_{mlm}^M = - \sum_{s=1}^{S_M} \log P(m_s \| M'), \mathcal{L}_{mlm}^P = - \sum_{s=1}^{S_P} \log P(p_s \| P'),$$

where  $m_s, p_s$  are the masked tokens,  $M', P'$  are the masked sequences,  $S_M$  and  $S_P$  are the number of masked tokens,  $\log$  is log-likelihood, and  $P$  means the conditional probability. We put discussions about our joint training strategy to leverage the unlabeled data and the common pre-training and fine-tuning strategy in Section 3.4.

**Cost Analysis.** Our cross-attention mechanism has an advantage over previous pairwise interaction [14] in terms of computational cost. Specifically, our method requires  $O((|D| + |T|) \times d)$  computations, where  $|D|$  is the drug sequence length,  $|T|$  is the target sequence length, and  $d$  is the dimension of the hidden state. The computations for protein-to-drug attention and drug-to-protein attention are  $O(|D| \times d)$  and  $O(|T| \times d)$ , respectively. In contrast, previous pairwise attention methods require  $O(|D| \times |T| \times d)$  computations as each token in one sequence attends to all tokens in the other one, which is more costly. In experiments, we have shown that our cross-attention module is both efficient and effective.

### Training Overview

For the unlabeled molecule  $M$  and protein  $P$ , the loss functions are  $\mathcal{L}_{mlm}^M, \mathcal{L}_{mlm}^P$ . Then together with the MLM loss  $\mathcal{L}_{mlm}^D, \mathcal{L}_{mlm}^T$  and the MSE loss  $\mathcal{L}_{mse}$  on the paired drug-target, the final training objective is

$$\mathcal{L} = \mathcal{L}_{mse} + \alpha * (\mathcal{L}_{mlm}^D + \mathcal{L}_{mlm}^T) + \beta * (\mathcal{L}_{mlm}^M + \mathcal{L}_{mlm}^P),$$

where  $\alpha$  and  $\beta$  are the coefficients to control the weights of different losses. For simplicity, we set  $\alpha$  to be the same as  $\beta$ .

### Discussion

The commonly adopted method to leverage unlabeled data is to do pre-train, and the pre-trained model serves as either good initialization (fine-tune-based utilization) or good feature extractors for downstream training (feature-based utilization). Both ways separate the pre-train and the downstream tasks training into two stages, while our strategy is to jointly train the pre-train and the downstream tasks in a multi-task framework and leverage both labeled and unlabeled data together. Two obvious advantages are: (1) Our joint training is super crucial for DTA prediction. The common strategy ignores the interaction during pre-train, which leads to a huge gap between the pre-train and fine-tune prediction [37] since DTA requires both drug and target for prediction, while the representations learned by our method can well capture the interaction between drug and target. (2) Our method can learn

**Table 1.** Performance of different methods on BindingDB IC<sub>50</sub> and K<sub>i</sub> datasets. The ↓ and ↑ indicate the directions of better results. We report the mean (std) results with three runs.

Dataset	IC <sub>50</sub>		K <sub>i</sub>	
	RMSE↓	PC↑	RMSE↓	PC↑
Random Forest	0.910	0.780	0.970	0.780
DeepAffinity [5]	0.780	0.840	0.840	0.840
DeepDTA [17]	0.782	0.848	-	-
MONN [14]	0.764	0.858	-	-
BACPI [18]	0.740	0.860	0.800	0.860
Our baseline	0.787 (0.002)	0.848 (0.003)	0.866 (0.003)	0.837 (0.002)
SSM-DTA	<b>0.712 (0.003)</b>	<b>0.878 (0.004)</b>	<b>0.792 (0.002)</b>	<b>0.863 (0.001)</b>

good representations from unlabeled data by MLM training and also the task-specific representations from DTA training, which hence can avoid the catastrophic forgetting problem [38] existed in pre-train/fine-tune based method. However, due to the semi-supervised training with large-scale unlabeled data, the training cost is increased compared to directly fine-tuning on an already pre-trained Transformer model (if already existed). From the experimental studies (Section 5.3), we find that our method achieves superior performances compared with the two-stage methods. In the future, we will focus on more efficient methods to better leverage the unlabeled data.

## Experiments

### Experimental Settings

**Data.** The unlabeled molecules and proteins are from PubChem [39] and Pfam [40]. We randomly sampled 10M molecules and proteins<sup>2</sup> for semi-supervised training. For supervised DTA data, we take from three widely used datasets, BindingDB, DAVIS, and KIBA. BindingDB [41] is a database of measured binding affinities, focusing on the interactions of targets with small drug-like molecules. The data is randomly split to 6:1:3 as train/valid/test sets. We study on the IC<sub>50</sub> and K<sub>i</sub> measure as previous works [5, 14]. DAVIS [42] contains selectivity assays of the kinase protein family and the relevant inhibitors with their respective dissociation constant (K<sub>d</sub>) values. KIBA [43] dataset includes kinase inhibitor bioactivities measured in K<sub>i</sub>, K<sub>d</sub>, and IC<sub>50</sub> metrics. DAVIS and KIBA are randomly split by 7:1:2 as train/valid/test sets as in DeepPurpose [6]. To further validate the generalization ability of our SSM-DTA, we follow [15] to evaluate SSM-DTA on DAVIS dataset with unknown drug setting.<sup>3</sup> The unknown drugs refer to the identification and selection of outliers from all the drug compounds using the substructural features based k-means algorithm [44]. For the affinity label, lower IC<sub>50</sub>/K<sub>i</sub>/K<sub>d</sub> values indicate stronger binding affinities. Following previous works [5, 6], to reduce the label range, the concentrations are transformed to logarithm scales:  $-\log_{10}(\frac{x}{10^9})$ , where  $x$  is IC<sub>50</sub>/K<sub>i</sub>/K<sub>d</sub> in the unit of nM. For KIBA dataset, we directly use the KIBA scores provided by the dataset, which is an aggregation of IC<sub>50</sub>, K<sub>i</sub>, and K<sub>d</sub> measurements. Higher KIBA scores indicates stronger binding affinities. More detailed descriptions about datasets can be found in Appendix.

**Model.** The molecule and protein encoders  $\mathcal{M}_D$ ,  $\mathcal{M}_T$  are Transformers, and each follows RoBERTa<sub>base</sub> architecture with 12 layers. The regression prediction head is a 2-layer MLP with **tanh** activation function. The compared baseline methods include traditional machine learning methods like linear regression, ridge regression, support vector regression (SVR), KronRLS [12], and deep learning methods like DeepDTA [17], DeepAffinity [5], MONN [14], SAGDTA [45], MGraphDTA [46], GeneralizedDTA [15], BACPI [18], GraphDTA [47], DeepPurpose [6] and DeepCDA [48]. More details about models and compared baselines models can be found in Appendix.

**Evaluation Metrics.** We use (i) mean square error (MSE), (ii) root mean square error (RMSE), (iii) pearson correlation coefficient (PC) [48], (iv) concordance index (CI) [49]. MSE and RMSE measure the difference between ground truth values and values predicted by the model, (v) R-squared ( $R^2$ ) [15].

$$MSE(t, p) = \frac{1}{n} \sum_{i=1}^n (t_i - p_i)^2,$$

$$RMSE(t, p) = \sqrt{\frac{1}{n} \sum_{i=1}^n (t_i - p_i)^2} = \sqrt{MSE(t, p)},$$

where  $t$  and  $p$  represent ground truth affinity score and model prediction. PC measures the linear correlation between ground truth values and values predicted by the model. This measure is varied between -1 and +1. If the two variables are completely correlated it takes +1 and if they are reversely correlated then it takes -1. If there is no correlation between variables then it takes zero [48].

$$R(t, p) = \frac{\sum_{i=1}^n (t_i - \bar{t})(p_i - \bar{p})}{\sqrt{\sum_{i=1}^n (t_i - \bar{t})^2} \sqrt{\sum_{i=1}^n (p_i - \bar{p})^2}},$$

where  $t$  and  $p$  represent ground truth affinity score and model prediction. CI is a model assessment measure introduced by [49]. It measures the probability of the concordance between the ground truth value and the predicted value. As suggested in [12], the CI can be used as an evaluation metric for the prediction accuracy in drug-target interaction task. It can be considered as a generalization of the area under the ROC curve(AUC) that is usually used in binary classification. The intuition behind the CI is whether the predicted binding affinity values of two random drug-target pairs were predicted in the same order as their actual values were or not [50].

$$CI = \frac{1}{Z} \sum_{i,j,i>j} \sigma(t_i > t_j) h(p_i - p_j),$$

where  $t_i$  and  $p_i$  denote ground truth affinity score and model prediction of the  $i$ -th sample,  $Z$  denotes the normalization

<sup>2</sup> We also study other sizes in Supplementary Materials.

<sup>3</sup> We do not evaluate on KIBA dataset with unknown drug setting as it is not open-sourced by [15]

**Table 2.** Performance of different methods on DAVIS and KIBA datasets. We report the mean (std) results with three runs.

Dataset	DAVIS		KIBA	
Method	MSE↓	CI↑	MSE↓	CI↑
Linear Regression	0.542 (-)	0.790 (-)	0.443 (-)	0.741 (-)
Ridge Regression	0.532 (-)	0.800 (-)	0.443 (-)	0.742 (-)
SVR	0.434 (-)	0.827 (-)	0.343 (-)	0.764 (-)
KronRLS [12]	0.329 (0.019)	0.847 (0.006)	0.852 (0.014)	0.688 (0.003)
GraphDTA [47]	0.263 (0.015)	0.864 (0.007)	0.183 (0.003)	0.862 (0.005)
DeepDTA [17]	0.262 (0.022)	0.870 (0.003)	0.196 (0.008)	0.864 (0.002)
DeepPurpose [6]	0.242 (0.009)	0.881 (0.005)	0.178 (0.002)	0.872 (0.001)
DeepCDA [48]	0.248 (-)	0.891 (0.003)	0.176 (-)	0.889 (0.002)
Our baseline	0.237 (0.001)	0.875 (0.003)	0.162 (0.002)	0.891 (0.002)
<b>SSM-DTA</b>	<b>0.219 (0.001)</b>	<b>0.890 (0.002)</b>	<b>0.154 (0.001)</b>	<b>0.895 (0.001)</b>

constant that equals the number of data pairs with different label values, and  $\sigma$  is a step function that returns one if condition statement is satisfied otherwise it returns zero. Also,  $h(x)$  is the Heaviside step function [12] and defined as follows:

$$h(x) = \begin{cases} 1, & \text{if } x > 0 \\ 0.5, & \text{if } x = 0 \\ 0, & \text{if } x < 0 \end{cases}$$

The range of value for CI is between 0 and 1 where the value of one denotes the best result [48].

$$C - index(t, p) = \frac{paired_{correct} + 0.5 \times pairs_{tied}}{pairs_{admissible}},$$

where  $pairs_{correct}$  is the number of pairs s.t. if  $t_x > t_y$ , then  $p_x > p_y$ , pairs;  $pairs_{tied}$  is the number of pairs where  $p_x = p_y$ ; and  $pairs_{admissible}$  is the number of all possible pairs. The C-index is the average of how often a model says X is greater than Y when, in the observed data, X is indeed greater than Y.  $R^2$  represents the proportion of the variance in the dependent variable that is predictable from the independent variable. The value of  $R^2$  ranges from 0 to 1. A higher  $R^2$  value indicates a better fit of the model to the data, meaning the model can better explain the variation in the dependent variable.

$$R^2(t, p) = 1 - \frac{\sum_{i=1}^n (t_i - p_i)^2}{\sum_{i=1}^n (t_i - \bar{t})^2}.$$

Following previous works [5, 14, 18, 15], results on BindingDB dataset are evaluated on RMSE and PC, results on DAVIS and KIBA datasets are evaluated by MSE and CI scores, and results on DAVIS dataset with unknown drug setting are evaluated on MSE and  $R^2$ .

### Performances on BindingDB

We first present the results on the BindingDB dataset. The  $IC_{50}$  and  $K_i$  results are shown in Table 1. In the table, ‘Our baseline’ refers to our implemented baseline model with two separate encoders, a cross-attention module, and a feed-forward prediction layer, without the semi-supervised multi-task training. From the table, we can see that our SSM-DTA method achieves the best performance in terms of both RMSE and PC metrics. For example, on  $IC_{50}$ , the RMSE is reduced from 0.787 to 0.712 with more than 7% improvement by comparing our baseline and SSM-DTA. When compared with previous state-of-the-art models, such as MONN (0.764) and

BACPI (0.740), our model surpasses their performances by about 3% – 5%. On  $K_i$ , SSM-DTA also achieves the lowest RMSE 0.792 and highest PC 0.863. These numbers clearly show the effectiveness of our SSM-DTA framework for binding affinity prediction.

### Performances on DAVIS and KIBA

The performance comparison on DAVIS and KIBA datasets is reported in Table 2. The sizes of these two datasets are relatively smaller than the BindingDB dataset, but we can also see that our method outperforms previous works with clear improvements. Specifically, on KIBA dataset, the MSE and CI scores of our implemented baseline are 0.162 and 0.891, which are already better than most existing works. Our proposed SSM-DTA model further improves the performances to be 0.154 MSE and 0.895 CI scores<sup>4</sup>. Similar observations are shown on DAVIS dataset. Therefore, we have demonstrated the power of SSM-DTA on both large and small DTA prediction tasks.

### Performances on DAVIS with Unknown Drug Setting

The performance comparison on DAVIS dataset with unknown drug setting is shown in Table 3. Our SSM-DTA model achieves an MSE of 0.8019 and an  $R^2$  score of 0.2803, outperforming all baselines. Notably, our SSM-DTA shows superior performance than GeneralizedDTA [15], which is specially designed for unknown drug settings. These results indicate that SSM-DTA has superior generalization capabilities on DTA pairs with unknown drugs.

## Study and Analysis

In this section, we present case visualizations of binding activities between drugs and targets, the application of virtual screening and target detection, visualization of drug features, and some other studies to show the impact of our SSM-DTA framework.

### Case Study of Drug-Target Binding

Deep learning models often lack interpretability. Based on our cross-attention mechanism, we gain a better understanding

<sup>4</sup> We do not directly compare with Affinity2Vec [51] and WGNN-DTA [52] due to different data splitting method: they use 5-fold cross-validation and we directly split the dataset proportionally.

**Table 3.** Performance of different methods on DAVIS dataset with unknown drug setting. \* means we select the best model from the original paper.

Method	MSE↓	$R^2$ ↑
DeepDTA [17]	1.0271	0.1454
GraphDTA [47]	0.8872	0.2037
SAGDTA [45]	1.1324	0.1654
MGraphDTA [46]	0.8532	0.2287
GeneralizedDTA* [15]	0.8467	0.2402
<b>SSM-DTA</b>	<b>0.8019</b>	<b>0.2803</b>

of the DTA prediction through interactive attention. In this subsection, we provide two case studies to visualize the atomic level attention on compound molecules and the amino acid level attention on proteins. For atomic level attention, we carry out the experiment to see the attention values of target→drug attention calculation, where the query is target protein and the key/value is compound. Therefore, the attention weights on each atom reflect the importance of the compound atoms for one specific target. Similarly, for amino acid level attention, the experiment is to see attention values of drug→target attention, where the query is compound and the key/value is target protein. The attention weights on each amino acid of a protein can reflect the importance of these amino acids to the corresponding drug compound.

Following [7], we choose the drug prochlorperazine (PCP) and its target S100A4 (UniProt ID), whose atomic structure is experimentally determined (PDB ID: 3M0W)<sup>5</sup>, for one example analysis. Prochlorperazine is a phenothiazine antipsychotic medicine used to treat anxiety or schizophrenia, and its structure-activity relationship (SAR) has been thoroughly explored. From Fig. 2a, we can see that the attention highlighted atoms of PCP are consistent with the SAR features, demonstrating that our model is capable of capturing key atomic groups interacting with proteins. The ground truth of structural binding site information can be clearly visualized from the protein-drug complex structure (PDB ID: 3M0W) in the same figure. Among 10 residues (out of 100) with the highest attention scores, 4 are located in the vicinity of the binding site. Interestingly, 3 residues (Leu42, Leu79, and Met85) are from one chain, and one residue (Cys3) is from the other chain. The second case is the GABA<sub>A</sub> receptor, a ligand-gated ion channel from *Erwinia chrysanthemi* (ELIC) (UniProt ID: P0C7B7). We analyze the interaction between GABA<sub>A</sub> and the drug flurazepam, whose key atoms are highlighted in Fig. 2b, corresponding to four atomic groups. Similar to the first case, the prediction results are assessed using the complex structure determined with crystallography method (PDB ID: 2YOE)<sup>6</sup>. As shown in Fig. 2b, four of the amino acids around the binding sites are identified based on the attention score using the flurazepam as query input. These identified amino acids are labeled to emphasize their close contact with the drug molecule.

These case studies clearly demonstrate the power of our model in identifying important atomic groups or amino acids. We would like to stress that the structure information was only used when assessing the predicted key amino acids in these case studies instead of our training method. Although other amino

**Table 4.** Ablation study of SSM-DTA. ‘PC’ is Pearson Correlation.

Module			MSE/RMSE↓	PC↑
Cross-attention	Paired MLM	Unlabeled Data	Valid/Test	Valid/Test
✓	✗	✗	0.625/0.787	0.846/0.848
✓	✗	✓	0.601/0.772	0.853/0.855
✓	✓	✗	0.545/0.735	0.866/0.868
✓	✓	✓	<b>0.513/0.712</b>	<b>0.875/0.878</b>

acids not within the immediate vicinity of the binding site may also have higher attention scores, we found that the model prediction results are significantly meaningful (see the above S100A4-PCP interactions). These results suggest that the SSM-DTA model learns important rules in drug-target interactions via the proposed training framework.

### Ablation Study


We conduct an ablation study to verify the effectiveness of each component: the MLM multi-task training, the cross-attention module, and the semi-supervised training with unlabeled data. The results are presented in Table 4 and show the valid and test MSE/RMSE and Pearson Correlation scores on the BindingDB IC<sub>50</sub> dataset. In the table, ‘Paired MLM’ refers to the MLM training performed only on paired drug-target data, and the cross-attention module is the default module in our baseline model. From the table, we observe the following: (1) MLM multi-task training on the original paired data plays an important role in DTA prediction. For instance, the valid MSE is decreased from 0.625 to 0.545 with ‘Paired MLM’, and the test RMSE 0.735 is already the best performance among previous works, e.g., BACPI (0.740). (2) Semi-supervised training on unlabeled data (without ‘Paired MLM’) also improves the performance, e.g., valid MSE reduction from 0.625 to 0.601 and test RMSE from 0.787 to 0.772. (3) With all components, the valid/test results are further improved to 0.513 and 0.712. Similar observations are shown on the PC metric. Therefore, it is obvious that each component has a positive effect on improving DTA prediction.

### Training Strategies Comparison


As discussed, we implemented a different strategy to leverage the large-scale unlabeled data. This is different from the common pre-train (on large-scale unlabeled data) and fine-tune (on supervised labeled data) strategies (Section 3.4). To compare these different strategies, we conduct a study on the BindingDB IC<sub>50</sub> dataset. The following three different training strategies are compared: (1) *Feature-based tuning*. Pre-training on large-scale unlabeled data, and the pre-trained model is fixed and used as a feature extractor to conduct subsequent tuning; (2) *Pre-training and fine-tuning*. Pre-training on large-scale unlabeled data, the pre-trained model and newly added cross-attention are trained to fine-tune DTA prediction; and (3) *Semi-supervised multi-task training*. This is our SSM-DTA strategy. We present the results in Table 5 for both valid and test datasets. The feature-based training strategy does not perform well due to the limited number of tuning parameters (only the newly added cross-attention module was fine-tuned). Our SSM performs best among the three strategies, outperforming the general pre-training and fine-tuning method. This supports our claim that separate pre-training on molecules or proteins ignores the importance

<sup>5</sup> <https://www.rcsb.org/structure/3M0W>

<sup>6</sup> <https://www.rcsb.org/structure/2YOE>



(a) S100A4 target and prochlorperazine (PCP). The left panel shows the 3D view of S100A4 with PCP. The right panel shows the 2D view of PCP, whose atoms with high attention scores are highlighted. The pharmacophore groups according to SAR are in dashed circles: (1) The blue circle is a nitrogen-containing basic group. The side chain substituted with piperazine has the strongest effect; (2) The green circle contains sulfur at 5-position and nitrogen at 10-position, which are associated with antipsychotic activity; (3) The yellow circle is an electron withdrawing group at 2-position enhancing drug activity.



(b) GABA<sub>A</sub> receptor and flurazepam. The 3D structure of the complex (PDB ID: 2YOE) and 2D representation of the flurazepam are shown on the left and right panels. Atoms of flurazepam with high attention scores are highlighted in red color, and the important groups according to SAR are circled: (1) The blue and green circle are electron-withdrawing groups that enhance activity; (2) The yellow circle is a saturated double bond at 4,5-position, which increases sedative and antidepressant effects; and (3) The group enclosed by the purple circle prolongs the efficacy.

**Fig. 2.** Case studies of protein targets and the corresponding ligands. The amino acids with high attention scores are shown in van der Waals representations and the drug compound molecules are in ball-stick format in 3D models. The amino acids near the binding sites are labeled with their names and residue indexes.

of interaction for DTA prediction, and highlights our SSM is a better choice for paired interaction-related tasks than pre-training and fine-tuning strategy.

**Table 5.** Different training strategies to leverage the unlabeled molecule and protein data. ‘PC’ stands for Pearson Correlation.

Training Strategies	Valid MSE↓	Valid PC ↑	Test RMSE↓	Test PC ↑
Our baseline	0.545	0.866	0.735	0.868
Feature-based tuning	0.638	0.840	0.795	0.843
Pre-training/fine-tuning	0.536	0.868	0.738	0.867
SSM-DTA	<b>0.513</b>	<b>0.875</b>	<b>0.712</b>	<b>0.878</b>

## Target Detection on DrugBank

To evaluate the application values and generalization capability of our model, we perform an experiment using the DrugBank [53] dataset, where most drugs and targets are excluded from the BindingDB training data. DrugBank contains the real-world drug-target pairs with different interaction types, and we take the drug-target pairs with ‘inhibitor’ like<sup>7</sup> interactions, whose activity is quantified as IC<sub>50</sub> scores. The DrugBank dataset includes 4351 targets, which interact with at least one drug. We carry out the test by limiting the drug dataset to those that interact with less than 20 target proteins (most of the drugs only interact with one target, making it more difficult to identify true targets). We randomly selected 100 drugs among those that satisfy the selection criteria, and predict the affinity scores between 100 drugs and 4351 targets. For each drug, the targets are ranked based on the predicted affinity scores, and we analyze the ranking position of the true targets out of 4351 candidates. The performance is evaluated by counting the number of correctly identified targets for these 100 drugs in the top-ranked candidates (labeled as Top-*N*). For these 100 drugs in this

test, **13** drugs have correctly identified their best candidate target (i.e., Top-1), a significant improvement compared to the baseline model that only predicts **5** pairs in the Top-1 category. If the candidate pool is relaxed to Top-5, our SSM-DTA model correctly identifies the targets for **18** drugs, while the baseline model finds **10**. This test result shows that our SSM-DTA model can be potentially useful in drug repurposing research, by predicting the targets for a given drug.

## Virtual Screening on EGFR

A practical scenario for DTA prediction is virtual screening, which involves screening a large number of molecules to identify potential drugs for a specific target. This is the opposite application of target detection discussed in the above section. In this study, we conduct an experiment to evaluate the screening ability of our DTA model. Specifically, we choose the Epidermal Growth Factor Receptor (EGFR) (PDB ID: P00533)<sup>8</sup> as the study target, since it is an important gene target that highly related to the cell lung cancer. For all the drugs in the DrugBank (total number 6848), we calculate the binding affinity between each drug and EGFR target sequence, then we rank all the drugs based on the predicted affinity score. From the top-ranked drugs, we find that Afatinib (DrugBank ID: DB08916)<sup>9</sup> is ranked **8<sup>th</sup>** among all the 6848 drugs (top 0.1%), and ‘Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy’ (from DrugBank introduction). This high ranking clearly demonstrates that our DTA prediction has great potential for virtual screening.


## Drug Feature Learning and Drug Grouping

In reality, multiple drugs can interact with the same target, and these drugs often bind to similar regions on the target.

<sup>7</sup> Including ‘aggregation inhibitor’, ‘weak inhibitor’, ‘inhibitory allosteric modulator’, ‘inhibitor’ and ‘translocation inhibitor’.

<sup>8</sup> <https://www.uniprot.org/uniprotkb/P00533/entry>

<sup>9</sup> <https://go.drugbank.com/drugs/DB08916>




**Fig. 3.** Visualized embeddings of 285 drugs that correspond to 5 targets from DrugBank dataset. Each color represents the drugs for one specific target. (a) shows the drug embeddings from the DVMP pre-trained model, (b) is from our baseline model, and (c) is from our SSM-DTA.

This intrinsic correspondence means that drugs for the same target possess some common properties that may not be directly observable with conventional statistical parameters. Deep learning models, however, are capable of capturing hidden features, which are more efficient in describing drug properties. To evaluate this, we grouped 285 drugs that interact with 5 targets from the DrugBank dataset based on the learned features of three models: our baseline model, the SSM-DTA trained model, and a strong pre-trained molecule model (DVMP [54]). The embedding of these drugs in the manifold is shown in Fig. 3, with colors indicating the corresponding targets. From the figure, we can see that both the baseline DTA and SSM-DTA models show distinguishable clusters, which can be mapped to the corresponding targets. In the case of the pre-trained DVMP model, only the two apparent clusters can be identified (the blue dots and the rest), suggesting that the target-specific features are not learned by the model. The SSM-DTA model further improves drug embedding, manifested in better-defined clusters than those of the baseline model. For example, the drugs in the green/orange groups are broadly spread in the baseline model embedding, but they are centralized into clusters in the SSM-DTA model embedding (Fig. 3c). This test result demonstrates that the drugs can be better grouped according to their targets. Such target-specific features learned by the SSM-DTA model can be a foundation for improved performance in DTA prediction.

## Deeper Understanding of SSM-DTA

### Training Analysis

We provide the training process analysis from the MSE value on both training and validation sets. We plot the corresponding values at each iteration in Fig 4 for both our baseline and SSM-DTA models. From the curve, we can observe that along the training process, the MSE values on both training and validation sets from our SSM-DTA method are lower than the baseline model. While the converged training MSE values are similar on the training set, the validation MSE of SSM-DTA model is much better than the baseline model. Besides, the SSM-DTA model converges faster than the baseline model. These curves demonstrate that model training can benefit from the proposed SSM-DTA framework to get faster convergence and higher accuracy and to achieve better performance in validation and test datasets.




**Fig. 4.** The MSE loss curves on BindingDB  $IC_{50}$  training and validation datasets along the training process. Results are from our implemented baseline model and our SSM-DTA method.


### Effects of Unlabeled Data and MLM Loss Weight

We first study the effects of the different data scales of the unlabeled molecules and proteins. Specifically, we vary the unlabeled dataset to be 1M, 5M, and 10M scales during training and evaluate the effects of these unlabeled data scales on the performance of the trained model. The validation MSE scores are reported in Fig. 5a. The figure shows that a larger unlabeled data scale will gradually improve the performance. Due to the computation resource limitation, we do not perform experiments on larger datasets. We suspect the reason for increased performance comes from data diversity. The larger unlabeled data can help the model to learn better-generalized representations from more diverse data so as to enhance the DTA prediction task.

Our method introduces the coefficient weights  $\alpha$  and  $\beta$  for MLM training, and we simply set  $\alpha$  to be the same as  $\beta$ . Therefore, it is also necessary to investigate its effect. Here the weight value is varied among  $\{0, 1, 5, 10, 20\}$ . Note that we do not use the cross-attention module here. Fig. 5b shows the results of validation MSE under different settings. We can see that the weight has a trade-off effect and the optimal weight is 5, around which the MSE value for the validation set is the lowest. This is expected since the goal of MLM training is different from DTA prediction and the reduction in the DTA prediction MSE requires a proper incorporation with MLM training.



(a) Varied scales of unlabeled protein and molecule.

(b) Varied coefficient weight  $\alpha$  and  $\beta$ , here  $\alpha = \beta$ .

**Fig. 5.** Effects of (a) varied scales of unlabeled molecule and protein data, and (b) varied MLM loss coefficient  $\alpha$  and  $\beta$ .

**Table 6.** Performance comparison on DAVIS and BindingDB  $K_i$ .

Dataset	DAVIS		BindingDB $K_i$	
	MSE↓	CI↑	RMSE↓	PC↑
Pairwise Attention	0.233 (0.002)	0.884 (0.002)	0.802 (0.001)	0.852 (0.002)
SSM-DTA	<b>0.219 (0.001)</b>	<b>0.890 (0.002)</b>	<b>0.792 (0.002)</b>	<b>0.863 (0.001)</b>

### Effectiveness of our Cross-attention Module

To show the effectiveness of our proposed cross-attention module, we replace it with pairwise attention that was used in DeepAffinity [5] for an experiment, and the results are shown in Table 6. The better results of SSM-DTA show that our cross-attention is not only more effective (better performance) but also more efficient (lower computation cost as discussed before).

### Conclusion

Predicting Drug-Target Affinity (DTA) is crucial in the drug discovery process, but it has been difficult to achieve using deep learning approaches due to limitations in supervised data. To address this issue, we propose three strategies to improve DTA prediction performance. We develop an SSM-DTA model that combines paired MLM training with a semi-supervised multi-task framework that leverages large-scale unlabeled data and an efficient cross-attention module for drug-target interaction. Experiments on multiple DTA benchmark datasets show improved performance of our method. We also demonstrate the ability of our model to generalize to unknown drugs and identify key atom groups and amino acids through three case studies. Additionally, we explore and demonstrate the target-specific features embedded in the SSM-DTA by grouping drugs according to their targets, providing an explanation for the improved performance of our proposed

method. In the future, we would like to explore the unification of structure and sequence methods in an efficient way.

### Limitations

Though our SSM-DTA framework achieves superior results on DTA tasks, it still has several limitations. First, as SSM-DTA is trained on both labeled and large-scale unlabeled data at the same time, the training cost is relatively high. For example, for BindingDB IC50 (training set size: 263,583), the overall training process was done on 8 NVIDIA V100 GPUs for 4.8 days. Second, while SSM-DTA performs well on benchmark datasets, actual validation of this method would require experimental results. Without such validation, there’s a risk of overfitting the specific datasets and not truly predicting drug-target affinity in real-world applications. Moreover, a predominant challenge with most drug-target affinity (DTA) prediction methods is their inability to generalize across different datasets, primarily due to the diversity in drugs and targets and different affinity types present within these datasets. These limitations are important for future exploration.

### Author Contributions Statement

Q.P. and L.W. conceived the experiments, Q.P. conducted the experiments, Q.P., L.W., and J.Z. analysed the results. Q.P. and L.W. wrote the manuscript, Y.X., S.X., and R.Y. reviewed the manuscript.

### Acknowledgments

The authors thank the anonymous reviewers for their valuable suggestions.

### Data Availability

The code and data for this study are available at <https://github.com/QizhiPei/SSM-DTA>.

### Funding

This work was partially supported by National Natural Science Foundation of China (NSFC Grant No. 62122089), Beijing Outstanding Young Scientist Program NO. BJJWZYJH012019100020098, and Intelligent Social Governance Platform, Major Innovation & Planning Interdisciplinary Platform for the “Double-First Class” Initiative, Renmin University of China, the Fundamental Research Funds for the Central Universities, and the Research Funds of Renmin University of China.

### References

- Steven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, Charles C Persinger, Bernard H Munos, Stacy R Lindborg, and Aaron L Schacht. How to improve r&d productivity: the pharmaceutical industry’s grand challenge. *Nature reviews Drug discovery*, 2010.
- Oleg Trott and Arthur J Olson. Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of computational chemistry*, 2010.

- Xuewei Liu, Danfeng Shi, Shuangyan Zhou, Hongli Liu, Huanxiang Liu, and Xiaojun Yao. Molecular dynamics simulations and novel drug discovery. *Expert opinion on drug discovery*, 2018.
- Masashi Tsubaki, Kentaro Tomii, and Jun Sese. Compound-protein interaction prediction with end-to-end learning of neural networks for graphs and sequences. *Bioinformatics*, 2019.
- Mostafa Karimi, Di Wu, Zhangyang Wang, and Yang Shen. Deepaffinity: interpretable deep learning of compound-protein affinity through unified recurrent and convolutional neural networks. *Bioinformatics*, 2019.
- Kexin Huang, Tianfan Fu, Lucas M Glass, Marinka Zitnik, Cao Xiao, and Jimeng Sun. Deeppurpose: a deep learning library for drug-target interaction prediction. *Bioinformatics*, 2020.
- Lifan Chen, Xiaoqin Tan, Dingyan Wang, Feisheng Zhong, Xiaohong Liu, Tianbiao Yang, Xiaomin Luo, Kaixian Chen, Hualiang Jiang, and Mingyue Zheng. Transformerpcpi: improving compound-protein interaction prediction by sequence-based deep learning with self-attention mechanism and label reversal experiments. *Bioinformatics*, 2020.
- Jacob Devlin, Ming-Wei Chang, Kenton Lee, and Kristina Toutanova. Bert: Pre-training of deep bidirectional transformers for language understanding. *arXiv:1810.04805*, 2018.
- Yinhan Liu, Myle Ott, Naman Goyal, Jingfei Du, Mandar Joshi, Danqi Chen, Omer Levy, Mike Lewis, Luke Zettlemoyer, and Veselin Stoyanov. Roberta: A robustly optimized bert pretraining approach. *arXiv:1907.11692*, 2019.
- Heng Luo, William Mattes, Donna L Mendrick, and Huixiao Hong. Molecular docking for identification of potential targets for drug repurposing. *Current topics in medicinal chemistry*, 2016.
- Anna Cichonska, Balaguru Ravikumar, Elina Parri, Sanna Timonen, Tapio Pahikkala, Antti Airola, Krister Wennerberg, Juho Rousu, and Tero Aittokallio. Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors. *PLoS computational biology*, 2017.
- Tapio Pahikkala, Antti Airola, Sami Pietilä, Sushil Shakyawar, Agnieszka Sz wajda, Jing Tang, and Tero Aittokallio. Toward more realistic drug-target interaction predictions. *Briefings in bioinformatics*, 2015.
- Tong He, Marten Heidemeyer, Fuqiang Ban, Artem Cherkasov, and Martin Ester. Simboost: a read-across approach for predicting drug-target binding affinities using gradient boosting machines. *Journal of cheminformatics*, 2017.
- Shuya Li, Fangping Wan, Hantao Shu, Tao Jiang, Dan Zhao, and Jianyang Zeng. Monn: a multi-objective neural network for predicting compound-protein interactions and affinities. *Cell Systems*, 2020.
- Shaofu Lin, Chengyu Shi, and Jianhui Chen. Generalizeddta: combining pre-training and multi-task learning to predict drug-target binding affinity for unknown drug discovery. *BMC bioinformatics*, 23(1):1–17, 2022.
- Weining Yuan, Guanxing Chen, and Calvin Yu-Chian Chen. Fusiondta: attention-based feature polymerizer and knowledge distillation for drug-target binding affinity prediction. *Briefings in Bioinformatics*, 23(1):bbab506, 2022.
- Hakime Öztürk, Arzucan Özgür, and Elif Ozkirimli. Deepdta: deep drug-target binding affinity prediction. *Bioinformatics*, 2018.
- Min Li, Zhangli Lu, Yifan Wu, and YaoHang Li. Bacpi: a bi-directional attention neural network for compound-protein interaction and binding affinity prediction. *Bioinformatics*, 2022.
- Tri Minh Nguyen, Thin Nguyen, and Truyen Tran. Mitigating cold-start problems in drug-target affinity prediction with interaction knowledge transferring. *Briefings in Bioinformatics*, 23(4):bbac269, 2022.
- Benedek Fabian, Thomas Edlich, Hél éna Gaspar, Marwin Segler, Joshua Meyers, Marco Fiscato, and Mohamed Ahmed. Molecular representation learning with language models and domain-relevant auxiliary tasks. *arXiv:2011.13230*, 2020.
- David Weininger. Smiles, a chemical language and information system. 1. introduction to methodology and encoding rules. *Journal of chemical information and computer sciences*, 1988.
- Weihua Hu, Bowen Liu, Joseph Gomes, Marinka Zitnik, Percy Liang, Vijay Pande, and Jure Leskovec. Strategies for pre-training graph neural networks. *arXiv:1905.12265*, 2019.
- Sheng Wang, Yuzhi Guo, Yuhong Wang, Hongmao Sun, and Junzhou Huang. Smiles-bert: large scale unsupervised pre-training for molecular property prediction. In *International conference on bioinformatics, computational biology and health informatics*, 2019.
- Seyone Chithrananda, Gabriel Grand, and Bharath Ramsundar. Chemberta: Large-scale self-supervised pretraining for molecular property prediction. *arXiv:2010.09885*, 2020.
- Shengchao Liu, Mehmet F Demirel, and Yingyu Liang. N-gram graph: Simple unsupervised representation for graphs, with applications to molecules. *NeurIPS*, 2019.
- Yu Rong, Yatao Bian, Tingyang Xu, Weiyang Xie, Ying Wei, Wenbing Huang, and Junzhou Huang. Self-supervised graph transformer on large-scale molecular data. *NeurIPS*, 2020.
- Jiezhong Qiu, Qibin Chen, Yuxiao Dong, Jing Zhang, Hongxia Yang, Ming Ding, Kuansan Wang, and Jie Tang. Gcc: Graph contrastive coding for graph neural network pre-training. In *SIGKDD*, 2020.
- Nadav Brandes, Dan Ofer, Yam Peleg, Nadav Rappoport, and Michal Linial. Proteinbert: A universal deep-learning model of protein sequence and function. *bioRxiv*, 2021.
- Roshan Rao, Nicholas Bhattacharya, Neil Thomas, Yan Duan, Peter Chen, John Canny, Pieter Abbeel, and Yun Song. Evaluating protein transfer learning with tape. *NeurIPS*, 32, 2019.
- Alexander Rives, Joshua Meier, Tom Sercu, Siddharth Goyal, Zeming Lin, Jason Liu, Demi Guo, Myle Ott, C Lawrence Zitnick, Jerry Ma, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. *Proceedings of the National Academy of Sciences*, 2021.
- Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, Łukasz Kaiser, and Illia Polosukhin. Attention is all you need. *NIPS*, 2017.
- Zhaoyang Niu, Guoqiang Zhong, and Hui Yu. A review on the attention mechanism of deep learning. *Neurocomputing*, 2021.

33. Pengfei Liu, Xipeng Qiu, and Xuanjing Huang. Recurrent neural network for text classification with multi-task learning. *arXiv:1605.05101*, 2016.
34. Seonwoo Min, Seunghyun Park, Siwon Kim, Hyun-Soo Choi, Byunghan Lee, and Sungroh Yoon. Pre-training of deep bidirectional protein sequence representations with structural information. *IEEE Access*, 2021.
35. Mathilde Caron, Piotr Bojanowski, Julien Mairal, and Armand Joulin. Unsupervised pre-training of image features on non-curated data. In *ICCV*, 2019.
36. Ze Liu, Jia Ning, Yue Cao, Yixuan Wei, Zheng Zhang, Stephen Lin, and Han Hu. Video swin transformer. *arXiv:2106.13230*, 2021.
37. Chengyi Wang, Yu Wu, Shujie Liu, Zhenglu Yang, and Ming Zhou. Bridging the gap between pre-training and fine-tuning for end-to-end speech translation. In *AAAI*, 2020.
38. Sanyuan Chen, Yutai Hou, Yiming Cui, Wanxiang Che, Ting Liu, and Xiangzhan Yu. Recall and learn: Fine-tuning deep pretrained language models with less forgetting. In *EMNLP*, 2020.
39. Sunghwan Kim, Paul A Thiessen, Evan E Bolton, Jie Chen, Gang Fu, Asta Gindulyte, Lianyi Han, Jane He, Siqian He, Benjamin A Shoemaker, et al. Pubchem substance and compound databases. *Nucleic acids research*, 2016.
40. Jaina Mistry, Sara Chuguransky, Lowri Williams, Matloob Qureshi, Gustavo A Salazar, Erik LL Sonnhammer, Silvio CE Tosatto, Lisanna Paladin, Shriya Raj, Lorna J Richardson, et al. Pfam: The protein families database in 2021. *Nucleic acids research*, 2021.
41. Tiqing Liu, Yuhmei Lin, Xin Wen, Robert N Jorissen, and Michael K Gilson. Bindingdb: a web-accessible database of experimentally determined protein–ligand binding affinities. *Nucleic acids research*, 2007.
42. Mindy I Davis, Jeremy P Hunt, Sanna Herrgard, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Michael Hocker, Daniel K Treiber, and Patrick P Zarrinkar. Comprehensive analysis of kinase inhibitor selectivity. *Nature biotechnology*, 2011.
43. Jing Tang, Agnieszka Szwarzajda, Sushil Shakyawar, Tao Xu, Petteri Hintsanen, Krister Wennerberg, and Tero Aittokallio. Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. *Journal of Chemical Information and Modeling*, 2014.
44. Sunghwan Kim, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian He, Qingliang Li, Benjamin A Shoemaker, Paul A Thiessen, Bo Yu, et al. Pubchem 2019 update: improved access to chemical data. *Nucleic acids research*, 47(D1):D1102–D1109, 2019.
45. Shugang Zhang, Mingjian Jiang, Shuang Wang, Xiaofeng Wang, Zhiqiang Wei, and Zhen Li. Sag-dta: prediction of drug–target affinity using self-attention graph network. *International Journal of Molecular Sciences*, 22(16):8993, 2021.
46. Ziduo Yang, Weihe Zhong, Lu Zhao, and Calvin Yu-Chian Chen. Mgraphdta: deep multiscale graph neural network for explainable drug–target binding affinity prediction. *Chemical science*, 13(3):816–833, 2022.
47. Thin Nguyen, Hang Le, Thomas P Quinn, Tri Nguyen, Thuc Duy Le, and Svetha Venkatesh. Graphdta: Predicting drug–target binding affinity with graph neural networks. *Bioinformatics*, 2021.
48. Karim Abbasi, Parvin Razzaghi, Antti Poso, Massoud Amanlou, Jahan B Ghasemi, and Ali Masoudi-Nejad. Deepcda: deep cross-domain compound–protein affinity prediction through lstm and convolutional neural networks. *Bioinformatics*, 2020.
49. Mithat Gönen and Glenn Heller. Concordance probability and discriminatory power in proportional hazards regression. *Biometrika*, 2005.
50. Mahsa Saadat, Armin Behjati, Fatemeh Zare-Mirakabad, and Sajjad Gharaghani. Drug-target binding affinity prediction using transformers. *bioRxiv*, 2022.
51. Maha A Thafar, Mona Alshahrani, Somayah Albaradei, Takashi Gojobori, Magbubah Essack, and Xin Gao. Affinity2vec: drug-target binding affinity prediction through representation learning, graph mining, and machine learning. *Scientific reports*, 12(1):4751, 2022.
52. Mingjian Jiang, Shuang Wang, Shugang Zhang, Wei Zhou, Yuanyuan Zhang, and Zhen Li. Sequence-based drug-target affinity prediction using weighted graph neural networks. *BMC genomics*, 23(1):1–17, 2022.
53. David S Wishart, Craig Knox, An Chi Guo, Savita Shrivastava, Murtaza Hassanali, Paul Stothard, Zhan Chang, and Jennifer Woolsey. Drugbank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic acids research*, 2006.
54. Jinhua Zhu, Yingce Xia, Tao Qin, Wengang Zhou, Houqiang Li, and Tie-Yan Liu. Dual-view molecule pre-training. *arXiv:2106.10234*, 2021.
55. Myle Ott, Sergey Edunov, Alexei Baevski, Angela Fan, Sam Gross, Nathan Ng, David Grangier, and Michael Auli. fairseq: A fast, extensible toolkit for sequence modeling. *arXiv:1904.01038*, 2019.
56. Diederik P Kingma and Jimmy Ba. Adam: A method for stochastic optimization. *arXiv:1412.6980*, 2014.
57. Saad Albawi, Tareq Abed Mohammed, and Saad Al-Zawi. Understanding of a convolutional neural network. In *ICET*. Ieee, 2017.
58. Larry R Medsker and LC Jain. Recurrent neural networks. *Design and Applications*, 2001.
59. Petar Velickovic, Guillem Cucurull, Arantxa Casanova, Adriana Romero, Pietro Lio, and Yoshua Bengio. Graph attention networks. *stat*, 2017.
60. Thomas N Kipf and Max Welling. Semi-supervised classification with graph convolutional networks. *arXiv:1609.02907*, 2016.
61. Keyulu Xu, Weihua Hu, Jure Leskovec, and Stefanie Jegelka. How powerful are graph neural networks? *arXiv:1810.00826*, 2018.

## Experimental Settings

The detailed experimental settings of our binding affinity prediction are introduced, including the datasets, model training, and compared baseline models.

### Datasets

Our method leverages both the limited DTA data and the large-scale unlabeled molecule and protein data. The introductions are as follows.

**Drug-Target Affinity Prediction Datasets** We use the widely adopted three benchmark datasets for DTA prediction, which are BindingDB, DAVIS, and KIBA datasets.

**BindingDB** [41] is a public database<sup>10</sup> of measured binding affinities, focusing on the interactions of targets with small drug-like molecules. Previous works like DeepAffinity [5], MONN [14] and BACPI [18] have been evaluated on half-maximal inhibitory concentration ( $IC_{50}$ ) values derived from the BindingDB database. For consistency purposes, we use the same BindingDB dataset in the test. The dataset contains 376,751  $IC_{50}$ -labeled samples, with 255,328 unique drugs and 2,782 unique targets. We randomly sample 70% for training (including 10% held out for validation), and 30% for test. In addition, there are three other measurements: concentration for 50% of maximal effect ( $EC_{50}$ ), inhibition constant ( $K_i$ ) and dissociation constant ( $K_d$ ), where the data size is smaller than  $IC_{50}$ . In our experiments, we also study the  $K_i$  measurement. The same data splitting and labeling protocols are applied. To reduce the label range, the concentrations are transformed to logarithm scales:  $-\log_{10}(\frac{x}{10^9})$ , where  $x$  is  $IC_{50}$  or  $K_i$  in the unit of nM.

**DAVIS** [42] dataset contains selectivity assays of the kinase protein family and the relevant inhibitors with their respective dissociation constant ( $K_d$ ) values. It has 30,056 DTA pairs with 68 unique drugs and 379 unique targets. Following DeepPurpose [6], we randomly sample 70% as the training set, 10% as the validation set, and 20% as the test set. Same as [13, 17], we also transform the raw values to logarithm scales in the same way as BindingDB data.

**KIBA** [43] dataset includes kinase inhibitor bioactivities measured in three metrics,  $K_i$ ,  $K_d$ , and  $IC_{50}$ . KIBA scores were constructed to optimize the consistency between  $K_i$ ,  $K_d$ , and  $IC_{50}$  by using the statistical information embedded in these quantities [17]. The final KIBA dataset we used has 118,254 DTA pairs with 2,068 unique drugs and 229 unique targets. We also randomly split 70%/10%/20% as train/valid/test dataset as in DeepPurpose [6].

**Unlabeled Molecule and Protein Datasets** The unlabeled molecule and protein datasets are from PubChem and Pfam respectively. Details are as follows.

**Pfam Dataset** [40] is a database<sup>11</sup> of protein families that includes their annotations and multiple sequence alignments generated using hidden Markov models. We use the amino acid sequence of protein extracted from the Pfam database as our

unlabeled protein data. The training set we randomly sampled consists of 10M protein sequences<sup>12</sup>.

**PubChem Dataset** [39] is the largest collection of freely accessible chemical information. We use Isomeric SMILES of molecules extracted from PubChem database<sup>13</sup> as our unlabeled molecule data. The training set we randomly sampled also consists of 10M molecules, which is consistent with unlabeled protein sequences.

### Model Configurations

We use two Transformer encoders for molecule encoder  $\mathcal{M}_D$  and protein encoder  $\mathcal{M}_T$ , and each follows RoBERTa<sub>base</sub> architecture that consists of 12 layers. The embedding/hidden size and the dimension of feed-forward layer are 768 and 3,072 respectively. The max lengths for molecule and protein are 512 and 1,024 respectively. The regression prediction head is 2-MLP layers with **tanh** activation function and the hidden dimension is 768. In general, the model has 178M parameters. The inference speed is 0.0061s/sample. Our model implementation is based on Fairseq [55] toolkit with version 0.10.2<sup>14</sup>.

### Training and Evaluation

**Training.** Our model is optimized by Adam [56] algorithm with learning rate  $1e^{-4}$ . The weight decay is 0.01. The dropout and attention dropout of two encoders is 0.1. The learning rate is warmed up in the first 10k update steps and then linearly decayed. The batch size is 32 sentences and we accumulated the gradients 8 times during training. The maximal training step is 200k. We set the optimal coefficients  $\alpha$  and  $\beta$  to be 2.0. **Evaluation.** We use (i) mean square error(MSE), (ii) root mean square error(RMSE), (iii) pearson correlation coefficient (PC) [48], (iv) concordance index (CI) [49] to evaluate the performance of our model on DTA regression task. To have a fair comparison with previous works, the results on the BindingDB dataset are evaluated on (ii) and (iii), and the results on the DAVIS and KIBA datasets are evaluated on (i) and (iv).

### Compared Baselines

We compare our SMT-DTA with the following baselines. We focus on state-of-the-art deep learning models as they have demonstrated superior performance over other methods.

- **SAGDTA** uses self-attention mechanisms on the molecular graph to get drug representations. Global and hierarchical pooling are evaluated on DAVIS and KIBA datasets.
- **MGraphDTA** uses a multiscale graph neural network inspired by chemical intuition for DTA prediction, incorporating a dense connection with 27 graph convolutional layers. MGraphDTA was evaluated on DAVIS and KIBA datasets.
- **DeepDTA** [17] uses CNN [57] on both SMILES and protein sequence to extract their features. Originally DeepDTA was evaluated on DAVIS and KIBA datasets, and MONN [14] evaluated DeepDTA on the BindingDB dataset.
- **DeepAffinity** [5] uses RNN [58] on both SMILES and protein sequence for unsupervised pre-training to learn their representations. After that, CNN layers are appended after

<sup>12</sup> We also study other sizes in Appendix.

<sup>13</sup> <https://pubchem.ncbi.nlm.nih.gov/>

<sup>14</sup> <https://github.com/pytorch/fairseq/tree/v0.10.2>

<sup>10</sup> <https://www.bindingdb.org/>

<sup>11</sup> <http://pfam.xfam.org/>

RNN for both molecules and proteins to make predictions. DeepAffinity was evaluated on the BindingDB dataset only.

- **MONN** [14] uses a GCN module and a CNN module to extract the features for molecule and protein, respectively. Then, a pairwise interaction module is introduced to link the molecule and protein. MONN was evaluated on the BindingDB dataset.
- **BACPI** [18] uses GAT [59] to encode molecule graph and CNN to encode protein sequence, respectively. A bi-directional attention is then introduced and the final integrated features are used to make affinity prediction. BACPI was evaluated on the BindingDB dataset.
- **KronRLS** [12] employs the Kronecker Regularized Least Squares (KronRLS) algorithm that utilizes 2D compound similarity-based representation of drugs and Smith-Waterman similarity-based representation of targets [12]. KronRLS was evaluated on DAVIS and KIBA datasets.
- **GraphDTA** [47] uses GCN [60], GAT [59], GIN [61] and GAT-GCN to encode molecular graph, and CNN to encode protein sequence. Finally, the concatenated features are passed to feed-forward layers for prediction. GraphDTA was evaluated on DAVIS and KIBA datasets.
- **DeepPurpose** [6] supports the training of customized DTA prediction models by implementing different molecule/protein encoders and various neural architectures. They were evaluated on DAVIS and KIBA datasets.

## Encoding Process of Transformer Encoder

We briefly introduce the encoding process of our drug/molecule encoder  $\mathcal{M}_D$  and target/protein encoder  $\mathcal{M}_T$ . Take the encoding of protein as an example. As previously defined, the input is the FASTA sequence of the protein, which consists of a  $[\text{cls}]_T$  token as the representation of the whole protein and amino acid tokens, e.g.,  $T = \{[\text{cls}]_T, \{t_i\}_{i=1}^{|T|}\}$ ,  $|T|$  is the protein length and  $t_i$  is the amino acid token. For simplicity, we denote  $t_0$  as the  $[\text{cls}]_T$  and  $T = \{t_i\}_{i=0}^{|T|}$ .

The first step is to convert each amino acid into its corresponding embedding vector. This is typically done using an embedding matrix.

$$E(T) = \{E(t_0), E(t_1), \dots, E(t_T)\},$$

$$E(t_i) = \text{EmbeddingMatrix}[i],$$

where  $E(t_i)$  is the embedding vector for amino acid  $t_i$ . To account for the position of each amino acid in the sequence, we add a positional encoding to each embedding vector. We denote the positional encoding for position  $i$  as  $PE(i)$ .

$$E'(t_i) = E(t_i) + PE(i),$$

where  $E'(t_i)$  is the embedding vector with positional encoding for amino acid  $t_i$ . Then the multi-head attention is used to allow the model to focus on different parts of the sequence simultaneously. Denote that we have  $N$  heads, for each head  $n$ , we compute

$$\text{AttnHead}_n = \text{Attn}(Q_n, K_n, V_n),$$

where  $Q_n = W_{Q_n}E'(T)$ ,  $K_n = W_{K_n}E'(T)$ ,  $V_n = W_{V_n}E'(T)$ .  $W_{Q_n}$ ,  $W_{K_n}$ , and  $W_{V_n}$  are learnable weight matrices for queries, keys, and values respectively for the  $n$ -th head. The attention scores are computed as the dot product of the query and key, scaled by the square root of the dimension  $d_n$ , and then passed through a softmax function.

$$\text{Attn}(Q_n, K_n, V_n) = \text{softmax}\left(\frac{Q_n K_n^T}{\sqrt{d_n}}\right) V_n,$$

The output from all heads is concatenated and linearly transformed:

$$\text{MultiHeadOutput} = [\text{AttnHead}_1, \dots, \text{AttnHead}_N] W_O,$$

where  $W_O$  is the output matrix. Each position in the multi-head attention output goes through a feed-forward network (the same one for each position):

$$\text{FFNOutput}_i = \text{FFN}(\text{MultiHeadOutput}_i).$$

The above multi-head attention and feed-forward network are stacked multiple times (i.e., number of layers). The output from the last feed-forward network is the encoded representation of the input sequence:  $H_T = \{h_{[\text{cls}]_T}, \{h_{t_i}\}_{i=1}^{|T|}\}$ , where  $[\text{cls}]_T$  is the whole representation of the protein and  $h_{t_i}$  represents the encoded hidden state of amino acid  $t_i$ .

The same encoding process also applies to the input drug SMILES, from which we get  $H_D = \{h_{[\text{cls}]_D}, \{h_{d_i}\}_{i=1}^{|D|}\}$ .